Epilepsy Impact Scale

Epilepsy Clinical Trial

Official title:

Questionnaire Development for a Comprehensive Scale to Measure the Impact of Epilepsy on Life.

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01833234
• Other study ID #: Stanford Epilepsy IRB 20523
• Status: Completed
• Phase: N/A
• First received: March 29, 2013
• Last updated: April 12, 2016
• Start date: July 2012
• Est. completion date: September 2014

Study information

• Verified date: April 2016
• Source: Stanford University
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Institutional Review Board
• Study type: Observational

Clinical Trial Summary

The investigators are developing a questionnaire that can quickly measure the impact that epilepsy has on a person's life. This questionnaire will be useful in following whether the impact of epilepsy increases, decreases or stays the same over time. The results also may point out areas that would benefit from discussion or attention in visits with your doctor.

Description:

The investigators have used a set of broad open-ended questions about the impact of epilepsy on a person's life to formulate a long list of questions to characterize the impact the seizures, medications, and comorbidities that you are having. In the future, this will be boiled down to a short list of questions.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 51
• Est. completion date: September 2014
• Est. primary completion date: September 2014
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Age 18 or more.

2. Patient has had at least 1 seizure in the past 365 days.

3. Patient can speak and understand English.

Exclusion Criteria:

1. Patients suspected of having one of the imitators of epilepsy, for example, syncope, sleep disorder, psychogenic nonepileptic seizures, will be excluded, even if they also have epileptic seizures.

2. Patients unwilling to spend the time doing the questionnaire.

Study Design

Observational Model: Cohort, Time Perspective: Prospective

Related Conditions & MeSH terms

• Epilepsy

Intervention

Other:
• Interviews and questionnaires

Locations

Country	Name	City	State
United States	Stanford University School of Medicine	Stanford	California

Sponsors (2)

Lead Sponsor	Collaborator
Stanford University	James & Carrie Anderson Fund for Research in Epilepsy

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Validation of a concise question set		Up to 1 year for question set validation, data presentation within up to 1.5 years	No
Secondary	Correlation of subscales	Correlation of subscales of the study questionnaire with previously validated scales, including QoLiE-39, NHS Seizure Severity Scale, Liverpool side effects scale, Beck Depression Index	Up to 1.5 years	No